Lannett Company, Inc.  

(Public, NYSE:LCI)   Watch this stock  
Find more results for LCI
17.05
-0.65 (-3.67%)
Feb 16 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 16.95 - 17.85
52 week 14.90 - 30.35
Open 17.65
Vol / Avg. 641,741.00/751,476.00
Mkt cap 645.23M
P/E 13.44
Div/yield     -
EPS 1.27
Shares 37.84M
Beta 2.51
Inst. own 104%
Apr 30, 2018
Q3 2018 Lannett Company Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Feb 7, 2018
Q2 2018 Lannett Company Inc Earnings Call - Webcast
Feb 7, 2018
Q2 2018 Lannett Company Inc Earnings Release
Jan 18, 2018
Lannett Company Inc Annual Shareholders Meeting (Estimated)
Jan 17, 2018
Lannett Company Inc Annual Shareholders Meeting
Dec 14, 2017
Lannett Company Inc at BMO Capital Markets Prescriptions for Success Healthcare Conference
Dec 13, 2017
Lannett Company Inc at Guggenheim Boston Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '17) 2017
Net profit margin 7.61% -0.09%
Operating margin 25.57% 13.56%
EBITD margin - 38.45%
Return on average assets 3.43% -0.03%
Return on average equity 9.62% -0.10%
Employees 1,126 -
CDP Score - -

Address

9000 State Rd
PHILADELPHIA, PA 19136-1615
United States - Map
+1-215-3339000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company's products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.

Officers and directors

Jeffrey Farber Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Timothy C. Crew Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Martin P. Galvan CPA Chief Financial Officer, Vice President - Finance, Treasurer
Age: 65
Bio & Compensation  - Reuters
John Kozlowski Corporate Chief Operating Officer
Age: 45
Bio & Compensation  - Reuters
Kevin R. Smith Senior Vice President - Sales and Marketing
Age: 57
Bio & Compensation  - Reuters
Robert Ehlinger Vice President - Logistics, Chief Information Officer
Age: 60
Bio & Compensation  - Reuters
Samuel H. Israel Vice President, General Counsel, Chief Legal Officer
Age: 56
Bio & Compensation  - Reuters
John M. Abt Vice President - Quality
Age: 52
Bio & Compensation  - Reuters
David Drabik Lead Independent Director
Age: 49
Bio & Compensation  - Reuters
Patrick G. LePore Independent Director
Age: 62
Bio & Compensation  - Reuters